HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Weider Move Free Advertising Strategy Key To Earnings Improvement

This article was originally published in The Tan Sheet

Executive Summary

Weider says a recently launched brand-building initiative for its Schiff division's Move Free joint supplement product line will help return the company to positive earnings in the coming year

You may also be interested in...



Weider

Firm's Schiff Move Free joint supplement sales fell 2.9% in the first quarter versus the prior year period which is "unacceptable, but does indicate we are starting to stabilize the brand," CEO Bruce Wood comments in Sept. 25 earnings call. In March, Weider implemented a brand-building initiative for Move Free that included over $12 mil. in ad spending to spur its sales (1"The Tan Sheet" Aug. 18, 2003, p. 13). Wood expects low, single-digit Move Free growth in Weider's 2004 fiscal year, driven by double-digit growth at year-end. The exec also says Weider plans to launch new products "branching into new broad human condition areas, an example being cardiovascular health," in 2005...

NBTY Aiming To Double Rexall Earnings; Closes Deal

NBTY plans to double newly acquired Rexall Sundown's earnings before interest, taxes, depreciation and amortization (EBITDA) to $78 mil. in the next nine months

Weider Move Free Relaunch Backed By $12-$15 Mil. Marketing Spend

Weider's Schiff division is promoting its revamped Move Free joint supplement line with a $12 mil. to $15 mil. "comprehensive marketing campaign," the firm announced March 26

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS129889

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel